6SEPTEMBER - 2021TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comBiosimulation is used extensively for pharmaceutical drug development to mimic the flow of diseases and then running the designed medicine through the simulation to observe its impact on both the disease and the body. The global biosimulation market is projected to reach USD 2881 billion by 2022 at a CAGR of 15.9 percent. Factors such as increase in R&D investments in the pharmaceutical and biotechnology industries, growing adoption of biosimulation software by regulatory bodies, and the need to curtail drug discovery and development costs are driving the growth of the market.The pharmaceutical companies segment accounts for a significant market share. This is due to the increasing adoption of in silico models for developing new drugs for cancer, diabetes, and central nervous system diseases. In addition, as biosimulation models grow in complexity, researchers are finding it more difficult to share, manage, and edit their models. The problem of sharing complex biomedical models is becoming severe with the lack of scalable standards for model representation and reuse. There is a growing need for tools that will help researchers efficiently build, manage, and reuse their biosimulation models. In this edition of Pharma Tech Outlook, we bring you the story of some of the most successful biosimulation solution providers that deliver the best outcomes for their clients. This edition also offers a combination of thought leadership from subject matter experts with real-life stories on fostering robust partnerships and exclusive insights from CIOs and CXOs. We hope this edition will provide you the assistance in choosing the right biosimulation solution provider according to your requirements. Let us know your thoughts!Curtailing Drug Discovery and Development Time and CostsTECH OUTLOOKTECH OUTLOOKCopyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.SEPTEMBER - 06 - 2021, Vol 07 - Issue 08 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerJaxon JaseEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:David Parker
< Page 5 | Page 7 >